Guardant Health (GH) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Guardant Health (NASDAQ: GH):

• 1/9/2026 – Guardant Health had its price target raised by analysts at Stifel Nicolaus from $100.00 to $120.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Guardant Health was given a new $135.00 price target on by analysts at Mizuho.
• 1/7/2026 – Guardant Health had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 1/5/2026 – Guardant Health had its price target raised by analysts at Guggenheim from $85.00 to $115.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Guardant Health was given a new $105.00 price target on by analysts at Evercore ISI. They now have an “in-line” rating on the stock.
• 1/5/2026 – Guardant Health had its “in-line” rating reaffirmed by analysts at Evercore ISI. They now have a $105.00 price target on the stock, up previously from $90.00.
• 12/22/2025 – Guardant Health had its price target raised by analysts at Canaccord Genuity Group Inc. from $100.00 to $125.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Guardant Health had its price target raised by analysts at Mizuho from $100.00 to $120.00. They now have an “outperform” rating on the stock.
• 12/15/2025 – Guardant Health had its price target raised by analysts at Leerink Partners from $115.00 to $155.00. They now have an “outperform” rating on the stock.
• 12/15/2025 – Guardant Health had its price target raised by analysts at Wells Fargo & Company from $93.00 to $120.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Guardant Health had its price target raised by analysts at Barclays PLC from $85.00 to $120.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Guardant Health had its price target raised by analysts at JPMorgan Chase & Co. from $90.00 to $120.00. They now have an “overweight” rating on the stock.
• 12/12/2025 – Guardant Health had its price target raised by analysts at BTIG Research from $100.00 to $140.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Guardant Health had its price target raised by analysts at Citigroup Inc. from $100.00 to $135.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Guardant Health had its price target raised by analysts at Morgan Stanley from $105.00 to $130.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CFO Michael Brian Bell sold 80,362 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.14, for a total value of $8,288,536.68. Following the sale, the chief financial officer owned 28,052 shares of the company’s stock, valued at $2,893,283.28. This trade represents a 74.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Chris Freeman sold 31,452 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $103.07, for a total value of $3,241,757.64. Following the transaction, the insider owned 25,987 shares in the company, valued at approximately $2,678,480.09. This represents a 54.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 436,552 shares of company stock worth $45,622,836 over the last quarter. Company insiders own 6.10% of the company’s stock.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.